Trial Profile
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Alkermes plc
- 18 May 2022 Results of post-hoc analysis presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 18 Sep 2017 Primary endpoint has been met. (Change from baseline in Clinical Global Impressions-Severity (CGI-S) scores), according to an Alkermes plc media release
- 18 Sep 2017 Positive 6-months topline results from this trial were presented at the 30th Annual Psych Congress (Psych Congress), according to an Alkermes plc media release